{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:06:09Z","timestamp":1789340769838,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40257-025-00993-1","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:16:44Z","timestamp":1762885004000},"page":"167-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials"],"prefix":"10.1007","volume":"27","author":[{"given":"Brian S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Gon\u00e7alo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Ugajin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Hua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy H.","family":"Praestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Makhija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2880-1995","authenticated-orcid":false,"given":"Simmi","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"7","key":"993_CR1","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/jdv.14570","volume":"32","author":"MP Pereira","year":"2018","unstructured":"Pereira MP, Steinke S, Zeidler C, Forner C, Riepe C, Augustin M, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059\u201365. https:\/\/doi.org\/10.1111\/jdv.14570.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"993_CR2","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","volume":"83","author":"AH Huang","year":"2020","unstructured":"Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559\u201365. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.183.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"993_CR3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","volume":"84","author":"S Elmariah","year":"2021","unstructured":"Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Mollanazar N, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol. 2021;84(3):747\u201360. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.025.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"993_CR4","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3872","volume":"101","author":"K Wikstrom","year":"2021","unstructured":"Wikstrom K, Verkko H, Sinikumpu SP, Jokelainen J, Tasanen K, Huilaja L. Comorbidities of prurigo nodularis in Finland between 1996 and 2019. Acta Derm Venereol. 2021;101(7):adv00508. https:\/\/doi.org\/10.2340\/00015555-3872.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"993_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1468-3083.2012.04481.x","volume":"27","author":"A Iking","year":"2013","unstructured":"Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, St\u00e4nder S. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol. 2013;27(5):550\u20137. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04481.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"993_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/cea.13954","volume":"51","author":"JD Hamilton","year":"2021","unstructured":"Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915\u201331. https:\/\/doi.org\/10.1111\/cea.13954.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"993_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4168\/aard.2024.12.1.26","volume":"12","author":"HJ Lee","year":"2024","unstructured":"Lee HJ, Yang E-A, Chun YH, Kim HH, Kim HS. Blood eosinophil counts as a biomarker for allergen sensitization in childhood allergic diseases in comparison with total IgE. Allergy Asthma Respir Dis. 2024;12(1):26\u201330. https:\/\/doi.org\/10.4168\/aard.2024.12.1.26.","journal-title":"Allergy Asthma Respir Dis"},{"issue":"2","key":"993_CR8","doi-asserted-by":"publisher","DOI":"10.5415\/apallergy.2020.10.e14","volume":"10","author":"M Nagata","year":"2020","unstructured":"Nagata M, Nakagome K, Soma T. Mechanisms of eosinophilic inflammation. Asia Pac Allergy. 2020;10(2):e14. https:\/\/doi.org\/10.5415\/apallergy.2020.10.e14.","journal-title":"Asia Pac Allergy"},{"issue":"7","key":"993_CR9","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/ced.14722","volume":"46","author":"P Aggarwal","year":"2021","unstructured":"Aggarwal P, Choi J, Sutaria N, Roh YS, Wongvibulsin S, Williams KA, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol. 2021;46(7):1277\u201384. https:\/\/doi.org\/10.1111\/ced.14722.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"993_CR10","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","volume":"140","author":"AH Huang","year":"2020","unstructured":"Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Investig Dermatol. 2020;140(2):480-3.e4. https:\/\/doi.org\/10.1016\/j.jid.2019.07.697.","journal-title":"J Investig Dermatol"},{"issue":"4","key":"993_CR11","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000246715","volume":"190","author":"M Tanaka","year":"1995","unstructured":"Tanaka M, Aiba S, Matsumura N, Aoyama H, Tagami H. Prurigo nodularis consists of two distinct forms: early-onset atopic and late-onset non-atopic. Dermatology. 1995;190(4):269\u201376. https:\/\/doi.org\/10.1159\/000246715.","journal-title":"Dermatology"},{"key":"993_CR12","unstructured":"US Food and Drug Administration. Dupixent: prescribing information. 2023. https:\/\/www.regeneron.com\/downloads\/dupixent_fpi.pdf. Accessed 26 May 2025."},{"key":"993_CR13","unstructured":"European Medicines Agency. Dupixent: summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf. Accessed 26 May 2025."},{"key":"993_CR14","unstructured":"Sanofi. Dupixent. Press release: Dupixent\u00ae (dupilumab) receives additional approval for the treatment of prurigo nodularis in Japan. June 26, 2023. https:\/\/www.sanofi.co.jp\/assets\/dot-jp\/pressreleases\/2023\/230626.pdf. Accessed 26 May 2025."},{"issue":"2","key":"993_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1314768.","journal-title":"N Engl J Med"},{"issue":"5","key":"993_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch G, Mollanazar N, St\u00e4nder S, Kwatra SG, Kim BS, Laws E, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023;29(5):1180\u201390. https:\/\/doi.org\/10.1038\/s41591-023-02320-9.","journal-title":"Nat Med"},{"issue":"1","key":"993_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-28.e13. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006.","journal-title":"Cell"},{"issue":"24","key":"993_CR18","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1610020.","journal-title":"N Engl J Med"},{"issue":"10209","key":"993_CR19","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1.","journal-title":"Lancet"},{"issue":"25","key":"993_CR20","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","volume":"387","author":"ES Dellon","year":"2022","unstructured":"Dellon ES, Rothenberg ME, Collins MH, Hirano I, Chehade M, Bredenoord AJ, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387(25):2317\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2205982.","journal-title":"N Engl J Med"},{"issue":"26","key":"993_CR21","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1804092.","journal-title":"N Engl J Med"},{"key":"993_CR22","unstructured":"Sanofi. Dupixent. Press release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study. September 11, 2024. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2024\/2024-09-11-05-00-00-2944237. Accessed 26 May 2025."},{"issue":"3","key":"993_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","volume":"389","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389(3):205\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2303951.","journal-title":"N Engl J Med"},{"issue":"1","key":"993_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jaci.2024.09.019","volume":"155","author":"CY Sun","year":"2025","unstructured":"Sun CY, Tesfaigzi Y, Lee GY, Chen YH, Weiss ST, Ma KS. Clinical effectiveness and safety of dupilumab in patients with chronic obstructive pulmonary disease: A 7-year population-based cohort study. J Allergy Clin Immun. 2025;155(1):219\u201322. https:\/\/doi.org\/10.1016\/j.jaci.2024.09.019.","journal-title":"J Allergy Clin Immun"},{"issue":"1","key":"993_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","volume":"154","author":"M Maurer","year":"2024","unstructured":"Maurer M, Casale TB, Saini SS, Ben-Shoshan M, Gim\u00e9nez-Arnau AM, Bernstein JA, et al. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J Allergy Clin Immunol. 2024;154(1):184\u201394. https:\/\/doi.org\/10.1016\/j.jaci.2024.01.028.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"993_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jdv.17870","volume":"36","author":"S St\u00e4nder","year":"2022","unstructured":"St\u00e4nder S, Zeidler C, Pereira M, Szepietowski JC, McLeod L, Qin S, et al. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation. J Eur Acad Dermatol Venereol. 2022;36(4):573\u201381. https:\/\/doi.org\/10.1111\/jdv.17870.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"993_CR27","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamadermatol.2020.3071","volume":"156","author":"M Kimel","year":"2020","unstructured":"Kimel M, Zeidler C, Kwon P, Revicki D, St\u00e4nder S. Validation of psychometric properties of the itch numeric rating scale for pruritus associated with prurigo nodularis: a secondary analysis of a randomized clinical trial. JAMA Dermatol. 2020;156(12):1354\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2020.3071.","journal-title":"JAMA Dermatol"},{"issue":"13","key":"993_CR28","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.2340\/00015555-3332","volume":"99","author":"C Riepe","year":"2019","unstructured":"Riepe C, Osada N, Reich A, Augustin M, Zeidler C, St\u00e4nder S. Minimal clinically important difference in chronic pruritus appears to be dependent on baseline itch severity. Acta Derm Venereol. 2019;99(13):1288\u201390. https:\/\/doi.org\/10.2340\/00015555-3332.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"993_CR29","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jaad.2019.07.022","volume":"82","author":"HF St\u00e4nder","year":"2020","unstructured":"St\u00e4nder HF, Elmariah S, Zeidler C, Spellman M, St\u00e4nder S. Diagnostic and treatment algorithm for chronic nodular prurigo. J Am Acad Dermatol. 2020;82(2):460\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2019.07.022.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"993_CR30","doi-asserted-by":"publisher","first-page":"adv00401","DOI":"10.2340\/00015555-3701","volume":"101","author":"C Zeidler","year":"2021","unstructured":"Zeidler C, Pereira MP, Augustin M, Spellman M, St\u00e4nder S. Investigator\u2019s global assessment of chronic prurigo: a new instrument for use in clinical trials. Acta Derm Venereol. 2021;101(2):adv00401. https:\/\/doi.org\/10.2340\/00015555-3701.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"993_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136. https:\/\/doi.org\/10.1111\/j.1365-2230.1994.tb01167.x.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"993_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Investig Dermatol. 2005;125(4):659\u201364. https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23621.x.","journal-title":"J Investig Dermatol"},{"issue":"7","key":"993_CR33","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/jdv.19800","volume":"38","author":"S Stander","year":"2024","unstructured":"Stander S, Kim BS, Guillemin I, Rhoten S, Wratten S, Brookes E, et al. Estimating meaningful change thresholds for skin pain-numeric rating scale, sleep-numeric rating scale and dermatology life quality index in patients with prurigo nodularis. J Eur Acad Dermatol Venereol. 2024;38(7):1401\u20139. https:\/\/doi.org\/10.1111\/jdv.19800.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"993_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361\u201370. https:\/\/doi.org\/10.1111\/j.1600-0447.1983.tb09716.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"993_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s0022-3999(96)00216-4","volume":"42","author":"C Herrmann","year":"1997","unstructured":"Herrmann C. International experiences with the Hospital Anxiety and Depression Scale\u2014a review of validation data and clinical results. J Psychosom Res. 1997;42(1):17\u201341. https:\/\/doi.org\/10.1016\/s0022-3999(96)00216-4.","journal-title":"J Psychosom Res"},{"issue":"Suppl. 2","key":"993_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.017","volume":"191","author":"S St\u00e4nder","year":"2024","unstructured":"St\u00e4nder S, Misery L, Yosipovitch G, Park CO, Li LF, Praestgaard A, et al. Dupilumab is efficacious in patients with prurigo nodularis regardless of baseline lesion severity: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2). Br J Dermatol. 2024;191(Suppl. 2):ljae266.017. https:\/\/doi.org\/10.1093\/bjd\/ljae266.017.","journal-title":"Br J Dermatol"},{"issue":"6","key":"993_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23214","volume":"34","author":"Y Hu","year":"2020","unstructured":"Hu Y, Liu S, Liu P, Mu Z, Zhang J. Clinical relevance of eosinophils, basophils, serum total IgE level, allergen-specific IgE, and clinical features in atopic dermatitis. J Clin Lab Anal. 2020;34(6):e23214. https:\/\/doi.org\/10.1002\/jcla.23214.","journal-title":"J Clin Lab Anal"},{"issue":"3","key":"993_CR38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/1346-8138.15212","volume":"47","author":"K Inui","year":"2020","unstructured":"Inui K, Ugajin T, Namiki T, Yokozeki H. Chronic prurigo: a retrospective study of 168 cases. J Dermatol. 2020;47(3):283\u20139. https:\/\/doi.org\/10.1111\/1346-8138.15212.","journal-title":"J Dermatol"},{"issue":"3","key":"993_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/cia2.12061","volume":"2","author":"T Ugajin","year":"2019","unstructured":"Ugajin T, Yokozeki H. Efficacy of anti-immunoglobulin E therapy in patients with prurigo: a pilot study. J Cutan Immunol Allergy. 2019;2(3):75\u201381. https:\/\/doi.org\/10.1002\/cia2.12061.","journal-title":"J Cutan Immunol Allergy"},{"issue":"12","key":"993_CR40","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/exd.14034","volume":"28","author":"M Campion","year":"2019","unstructured":"Campion M, Smith L, Gatault S, M\u00e9tais C, Buddenkotte J, Steinhoff M. Interleukin-4 and interleukin-13 evoke scratching behaviour in mice. Exp Dermatol. 2019;28(12):1501\u20134. https:\/\/doi.org\/10.1111\/exd.14034.","journal-title":"Exp Dermatol"},{"key":"993_CR41","doi-asserted-by":"publisher","first-page":"1258823","DOI":"10.3389\/fnmol.2023.1258823","volume":"16","author":"MR Mack","year":"2023","unstructured":"Mack MR, Miron Y, Chen F, Miller PE, Zhang A, Korotzer A, et al. Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli. Front Mol Neurosci. 2023;16:1258823. https:\/\/doi.org\/10.3389\/fnmol.2023.1258823.","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"993_CR42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.anai.2023.08.008","volume":"131","author":"KL Auyeung","year":"2023","unstructured":"Auyeung KL, Kim BS. Emerging concepts in neuropathic and neurogenic itch. Ann Allergy Asthma Immunol. 2023;131(5):561\u20136. https:\/\/doi.org\/10.1016\/j.anai.2023.08.008.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"993_CR43","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","volume":"138","author":"M Feld","year":"2016","unstructured":"Feld M, Garcia R, Buddenkotte J, Katayama S, Lewis K, Muirhead G, et al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol. 2016;138(2):500-8.e24. https:\/\/doi.org\/10.1016\/j.jaci.2016.02.020.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"993_CR44","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jaci.2023.08.017","volume":"153","author":"B Kim","year":"2024","unstructured":"Kim B, Rothenberg ME, Sun X, Bachert C, Artis D, Zaheer R, et al. Neuroimmune interplay during type 2 inflammation: symptoms, mechanisms, and therapeutic targets in atopic diseases. J Allergy Clin Immunol. 2024;153(4):879\u201393. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.017.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"993_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cyto.2015.05.010","volume":"75","author":"J Zhu","year":"2015","unstructured":"Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine. 2015;75(1):14\u201324. https:\/\/doi.org\/10.1016\/j.cyto.2015.05.010.","journal-title":"Cytokine"},{"key":"993_CR46","doi-asserted-by":"publisher","first-page":"1301817","DOI":"10.3389\/fimmu.2023.1301817","volume":"14","author":"Y Shao","year":"2023","unstructured":"Shao Y, Wang D, Zhu Y, Xiao Z, Jin T, Peng L, et al. Molecular mechanisms of pruritus in prurigo nodularis. Front Immunol. 2023;14:1301817. https:\/\/doi.org\/10.3389\/fimmu.2023.1301817.","journal-title":"Front Immunol"},{"issue":"10","key":"993_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105164","volume":"25","author":"HJ Yook","year":"2024","unstructured":"Yook HJ, Lee JH. Prurigo nodularis: pathogenesis and the horizon of potential therapeutics. Int J Mol Sci. 2024;25(10):5164. https:\/\/doi.org\/10.3390\/ijms25105164.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"993_CR48","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","volume":"389","author":"SG Kwatra","year":"2023","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389(17):1579\u201389. https:\/\/doi.org\/10.1056\/NEJMoa2301333.","journal-title":"N Engl J Med"},{"issue":"2","key":"993_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00403-019-01972-3","volume":"312","author":"JK Nguyen","year":"2020","unstructured":"Nguyen JK, Austin E, Huang A, Mamalis A, Jagdeo J. The IL-4\/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets. Arch Dermatol Res. 2020;312(2):81\u201392. https:\/\/doi.org\/10.1007\/s00403-019-01972-3.","journal-title":"Arch Dermatol Res"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00993-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00993-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00993-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:51:01Z","timestamp":1769849461000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00993-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["993"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00993-1","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Brian S. Kim is a co-founder of Alys Pharmaceuticals, reported acting as a consultant for 23andMe, Abrax Japan, AbbVie, Almirall, Amagma, Amgen, Arcutis Biotherapeutics, Arena Pharmaceuticals, Argenx, AstraZeneca, Bellus Health, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Clexio Biosciences, CymaBay Therapeutics, Eli Lilly, Escient Pharmaceuticals, Evommune, Galderma, Genentech, Granular Therapeutics, GSK, Guidepoint Global, Incyte, Innovaderm Research, Janssen Pharmaceuticals, Kiniksa Pharmaceuticals, LEO Pharma, Medicxi, Micreos, Novartis, OM Pharma, Pfizer, RecensMedical, Regeneron Pharmaceuticals Inc., Sanofi, Septerna, Shaperon, Teva, Third Harmonic Bio, Third Rock Ventures, Trevi Therapeutics, Triveni, Vial, and WebMD; reported serving as an advisory board member for Cara Therapeutics, Celgene, Kiniksa Pharmaceuticals, Menlo Therapeutics, Regeneron Pharmaceuticals Inc., Sanofi, and Theravance Biopharma; is a stockholder in Abrax Japan, Klirna Biotech, Locus Biosciences, Nuogen Pharma, and RecensMedical; is a patent holder for the use of Janus kinase 1 inhibitors for chronic pruritus (patent pending for the use of Janus kinase inhibitors for interstitial cystitis); is the founder of and chief scientific officer at Nuogen Pharma; and reports research grants from Cara Therapeutics and LEO Pharma. Margarida Gon\u00e7alo reported serving as an advisory board member and\/or speaker at AbbVie, Almirall, AstraZeneca, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, and Takeda. Tsukasa Ugajin reported giving lectures for AbbVie, Kaken, Kyorin Pharmaceutical, Maruho, Mitsubishi Tanabe Pharma, Novartis, Sanofi, Taiho, and Takeda. Xing-Hua Gao reported serving as an investigator with AbbVie, Boehringer Ingelheim, Novartis, Pfizer, and Sanofi; as a consultant and advisory board member with AbbVie, AstraZeneca, BMS, Eli Lilly, Huarun, JiaLan, LEO Pharma, Pfizer, Puqi, and Sanofi; and as a speaker for Eli Lilly, GSK, Janssen, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Regeneron Pharmaceuticals Inc., and Sanofi. Amy H. Praestgaard, Simmi Wiggins, and Melanie Makhija are employees of Sanofi, and may hold stock and\/or stock options in the company. Joseph Zahn and Ashish Bansal are employees and shareholders of Regeneron Pharmaceuticals Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest\/competing interests"}},{"value":"This study was conducted in accordance with ethical standards of the responsible committees and the Declaration of Helsinki 1964 and its later amendments, and with the International Council for Harmonisation guidelines for Good Clinical Practice. The trial was overseen by an independent data and safety monitoring board. The protocol was reviewed and approved by institutional review boards\/ethics committees at all centers. All patients provided written informed consent before participating in the trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all patients or their proxies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Qualified researchers may request access to patient-level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient-level data will be anonymized, and study documents will be redacted to protect the privacy of our trial participants. Further details on Sanofi\u2019s data-sharing criteria, eligible studies, and process for requesting access can be found at:\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"SW and JZ had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors contributed to the study concept and design and all participated in the acquisition, analysis, or interpretation of data. All authors participated in the drafting of the manuscript and critical revision of the manuscript for important intellectual content. AHP performed the statistical analysis. SW and JZ were responsible for study supervision.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}